ArticleBMC endocrine disorders2026
Circulating spexin and adiponectin as early biomarkers of insulin resistance in pediatric obesity.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInsulin resistance (IR) is a central pathological feature of childhood obesity. Spexin (SPX), an emerging endogenous metabolic regulatory peptide, plays a key role in regulating energy metabolism. This study aimed to evaluate the association between IR and serum levels of SPX and adiponectin (ADP) and assess their biomarker potential for predicting IR in children with obesity.
methodsIn total, the study enrolled 104 children (40 normal weight and 64 obese) aged 7–18 years. Further, children with obesity were categorized as having IR (n = 37) or not (n = 27) using a homeostatic model assessment of IR (HOMA-IR) cutoff of ≥ 3.0. Anthropometric measurements; biochemical profiles (including glucose, lipid, and liver enzyme levels); and serum concentrations of SPX, Gremlin-1, ADP, leptin (LEP), and tumor necrosis factor-alpha (TNF-α) were evaluated. The statistical analyses included correlation tests, multiple linear regression to identify independent determinants of HOMA-IR, and receiver operating characteristic (ROC) curve analysis to assess diagnostic performance.
resultsChildren with obesity and IR exhibited significantly lower serum SPX levels compared with those without IR, indicating a biphasic pattern characterized by a “compensatory increase” followed by a “decompensated decrease.” Multiple linear regressions identified triglycerides (β = 0.211, p = 0.021), SPX (β = −0.398, p = 0.049), and ADP (β = −0.577, p = 0.005) as independent factors associated with HOMA-IR. ROC curve analysis revealed that ADP (area under the curve [AUC] = 0.634) and SPX (AUC = 0.602) had significant, albeit modest, diagnostic value for predicting IR, outperforming Gremlin-1, LEP, and TNF-α.
conclusionsSerum SPX and ADP levels are significantly associated with IR in children with obesity and show potential as complementary early biomarkers. The biphasic change in SPX, characterized by an initial compensatory rise followed by a decompensatory decline, suggests a complex role in metabolic adaptation and failure, underscoring its pathophysiological relevance in the progression from obesity to IR. Thus, a screening approach that combines SPX and ADP may improve early identification of children at risk of obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.